Search Result

Results for "

Alcoholic Liver Disease

" in MedChemExpress (MCE) Product Catalog:

By Targets:	17β-HSD (2) Acyltransferase (1) Adiponectin Receptor (1) AMPK (5) Apoptosis (2) Autophagy (1) Bcl-2 Family (2) Calcium Channel (1) Cannabinoid Receptor (1) Caspase (3) Endogenous Metabolite (8) Ferroptosis (1) FXR (2) Glutathione Peroxidase (1) iGluR (1) Interleukin Related (2) Isotope-Labeled Compounds (1) JAK (1) LDLR (1) MDM-2/p53 (1) Na+/K+ ATPase (1) NF-κB (3) NOD-like Receptor (NLR) (2) P2X Receptor (1) PCSK9 (1) Phosphodiesterase (PDE) (1) PPAR (5) Pyroptosis (2) Reactive Oxygen Species (2) SOD (1) STAT (1) Stearoyl-CoA Desaturase (SCD) (2) TGF-β Receptor (1) TNF Receptor (2) Toll-like Receptor (TLR) (3)
By Research Areas:	Cancer (5) Cardiovascular Disease (7) Infection (3) Inflammation/Immunology (15) Metabolic Disease (26) Neurological Disease (2)

By Targets:

17β-HSD (2)

Acyltransferase (1)

Adiponectin Receptor (1)

AMPK (5)

Apoptosis (2)

Autophagy (1)

Bcl-2 Family (2)

Calcium Channel (1)

Cannabinoid Receptor (1)

Caspase (3)

Endogenous Metabolite (8)

Ferroptosis (1)

FXR (2)

Glutathione Peroxidase (1)

iGluR (1)

Interleukin Related (2)

Isotope-Labeled Compounds (1)

JAK (1)

LDLR (1)

MDM-2/p53 (1)

Na+/K+ ATPase (1)

NF-κB (3)

NOD-like Receptor (NLR) (2)

P2X Receptor (1)

PCSK9 (1)

Phosphodiesterase (PDE) (1)

PPAR (5)

Pyroptosis (2)

Reactive Oxygen Species (2)

SOD (1)

STAT (1)

Stearoyl-CoA Desaturase (SCD) (2)

TGF-β Receptor (1)

TNF Receptor (2)

Toll-like Receptor (TLR) (3)

By Research Areas:

Cancer (5)

Cardiovascular Disease (7)

Infection (3)

Inflammation/Immunology (15)

Metabolic Disease (26)

Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: LXR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N9182

Zeaxanthin dipalmitate Physalien	Adiponectin Receptor P2X Receptor Autophagy	Inflammation/Immunology
Zeaxanthin dipalmitate (Physalien) is a wolfberry-derived carotenoid, has anti-inflammatory and anti-oxidative stress effects. Zeaxanthin dipalmitate directly interact with p2X7 receptor (K_d=81.2 nM) and adiponectin receptor 1 (AdipoR1; K_d=533 nM) in a positive dose-dependent manner. Zeaxanthin dipalmitate restores mitochondrial autophagy functions suppressed by ethanol intoxication. Zeaxanthin dipalmitate can be used in the research of alcoholic fatty liver disease (AFLD) and retinitis pigmentosa (RP) .

HY-160004

PXL770	AMPK	Others
PXL770 is a direct AMP kinase activator. PXL770 can be used in the research of non-alcoholic fatty liver disease (NAFLD) .

HY-W082785A

L6H21	TNF Receptor Interleukin Related Toll-like Receptor (TLR) NF-κB NOD-like Receptor (NLR) Apoptosis Caspase Bcl-2 Family Reactive Oxygen Species	Neurological Disease Metabolic Disease Inflammation/Immunology
L6H21, a Chalcone (HY-121054) derivative, is an orally active, potent and specific myeloid differentiation 2 (MD-2) inhibitor. L6H21 directly binds to MD-2 protein with a high affinity and low K_D value of 33.3?μM, blocking the formation of the LPS-TLR4/MD-2 complex. L6H21 inhibits LPS-induced expression of TNF-α and IL-6 in RAW264.7 macrophages, with IC₅₀ values of 6.58 and 8.59 μM, respectively. L6H21 can be used for alcoholic liver disease, metabolic disturbance and neuroinflammation research .

HY-111179

ML261	Others	Inflammation/Immunology
ML261 is a hepatic lipid droplets formation inhibitor with an IC₅₀ value of 69.7 nM. ML261 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and inflammation .

HY-126967A

1-Palmitoyl-sn-glycerol 3-phosphate 1-P-GPA	Others	Metabolic Disease
1-Palmitoyl-sn-glycerol 3-phosphate (1-P-GPA) is an endogenous metabolite. 1-Palmitoyl-sn-glycerol 3-phosphate can be used for the research of non‐alcoholic fatty liver disease .

HY-W337335

1-Palmitoyl-sn-glycerol 3-phosphate sodium salt 1-P-GPA sodium salt	Endogenous Metabolite	Metabolic Disease
1-Palmitoyl-sn-glycerol 3-phosphate (sodium salt) (1-P-GPA (sodium salt)) is an endogenous metabolite. 1-Palmitoyl-sn-glycerol 3-phosphate (sodium salt) can be used in the study of non-alcoholic fatty liver disease .

HY-145581

Mitiperstat AZD4831	Glutathione Peroxidase	Cardiovascular Disease
Mitiperstat (AZD4831) is an effective oral inhibitor of myeloperoxidase (MPO). Mitiperstat can reduce inflammation and improve microvascular function, and it can be used in studies related to heart failure, preserved or mildly reduced ejection fraction, non-alcoholic fatty liver disease, and chronic obstructive pulmonary disease .

HY-16521

VX-166	Caspase	Inflammation/Immunology
VX-166, a pan caspase inhibitor, can be used for the research of Non- Alcoholic Fatty Liver Disease (NAFLD), nonalcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), and other diseases involving fibrosis, steatosis, or inflammation of the liver .

HY-N9921

Antcin A	Pyroptosis NOD-like Receptor (NLR)	Inflammation/Immunology
Antcin A is a potent NLRP3 inhibitor that inhibits the assembly and activation of the NLRP3 inflammasome. Antcin A can inhibit Kupffer cell pyroptosis and has liver protective activity. Antcin A can be used to study inflammation, such as non-alcoholic fatty liver disease .

HY-109089

Epeleuton	Others	Others
Epeleuton is a second-generation synthetic N-3 fatty acid derivative with activity in patients with non-alcoholic fatty liver disease, although it did not reach the primary endpoints of alanine aminotransferase and liver stiffness, but it can significantly reduce triglycerides, glycated hemoglobin, plasma glucose and inflammatory markers.

HY-116444A

16-HETE	Na+/K+ ATPase	Cardiovascular Disease Inflammation/Immunology
16-HETE is arachidonic acid metabolite through subterminal hydroxylation by cytochrome P-450. 16-HETE exhibits vasodilatory and PMN inhibitory effects and serves as biomarker for early stages of non-alcoholic fatty liver disease .

HY-103479

GOAT-IN-1	Acyltransferase	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
GOAT-IN-1 is an inhibitor of ghrelin O-acyltransferase (GOAT), which could be useful for the prophylaxis or treatment of obesity, diabetes, hyperlipidemia, metabolic, non-alcoholic fatty liver, steatohepatitis, sarcopenia, appetite control, alcohol/narcotic dependence, Alzheimer’s disease, Parkinson’s disease, cerebrovascular dementia, cerebral apoplexy, cerebral infarction, cardic disease, some kind of tumors.

HY-111180

ML262	Endogenous Metabolite	Metabolic Disease
ML-262 is an inhibitor of hepatic lipid droplet formation (IC₅₀=6.4 nM in murine AML-12 cells), which is associated with non-alcoholic fatty liver disease.1 ML-262 does not induce cytotoxicity (up to 33 μM) or inhibit fatty acid uptake (up to 50 μM).

HY-N0592

Demethyleneberberine 1 Publications Verification	NF-κB AMPK	Infection Metabolic Disease Inflammation/Immunology Cancer
Demethyleneberberine is a natural mitochondria-targeted antioxidant. Demethyleneberberine alleviates mice colitis and inhibits the inflammatory responses by inhibiting NF-κB pathway and regulating the balance of Th cells. Demethyleneberberine could serve as a AMPK activator for treating non-alcoholic fatty liver disease (NAFLD) .

HY-N0592A

Demethyleneberberine chloride 1 Publications Verification	NF-κB AMPK	Infection Metabolic Disease Inflammation/Immunology Cancer
Demethyleneberberine chloride is a natural mitochondria-targeted antioxidant. Demethyleneberberine chloride alleviates mice colitis and inhibits the inflammatory responses by inhibiting NF-κB pathway and regulating the balance of Th cells. Demethyleneberberine chloride could serve as a AMPK activator for researching non-alcoholic fatty liver disease (NAFLD) .

HY-W013215

Adrenic acid cis-7,10,13,16-Docosatetraenoic acid	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
Adrenic Acid (cis-7,10,13,16-Docosatetraenoic acid) is a naturally polyunsaturated fatty acid in the adrenal gland, brain, kidney, and vasculature. Adrenic Acid can regulate the vascular tone in arteries of the adrenal cortex. Adrenic Acid also is an inflammation enhancer in non-alcoholic fatty liver disease .

HY-W018392

Mono-(2-ethylhexyl) phthalate Maximum Cited Publications 7 Publications Verification MEHP; Phthalic acid mono-2-ethylhexyl ester	Endogenous Metabolite	Metabolic Disease
Mono-(2-ethylhexyl) phthalate (MEHP) is a major bioactive metabolite of diethylhexyl phthalate (DEHP). Mono-(2-ethylhexyl) phthalate can promote fatty acid synthesis in hepatocytes by regulating the expression of relevant genes and proteins, contributing to non-alcoholic fatty liver disease (NAFLD) .

HY-161979

HSD17B13-IN-103	17β-HSD	Cancer
HSD17B13-IN-103 (Compound 44) is a HSD17B13 inhibitor. HSD17B13-IN-103 can be used in the study of non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) .

HY-P10133

PRDX3(103-112) SO3 modified, human	Ferroptosis	Metabolic Disease
PRDX3(103-112) SO3 modified, human is a marker of ferroptosis, and can be used for liver diseases study .

HY-157457

Z21090	Phosphodiesterase (PDE)	Metabolic Disease
Z21090 (ZL40) is a potent inhibitor of PDE4 with the IC₅₀ value of 37.4 nM and oral bioavailability. Z21090 plays an important role in alcohol-related diseases research .

HY-151959

FXR agonist 4	FXR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
FXR agonist 4 (compound 10a) is an agonist of farnesoid X receptor (FXR) with an EC₅₀ value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of non-alcoholic fatty liver disease (NAFLD) .

HY-139230

OLHHA	Cannabinoid Receptor PPAR	Metabolic Disease
OLHHA is a dual CB1 receptor antagonist and PPARα agonist. OLHHA also is a alcohol intake inhibitor with an EC₅₀ value of 0.2 mg/kg. OLHHA reduces both hepatic lipid accumulation and circulating triglyceride levels. OLHHA shows anti-steatotic activity and has the potential for the research of non-alcoholic fatty liver disease (NAFLD) .

HY-W013215R

Adrenic acid (Standard)	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
Adrenic acid (Standard) is the analytical standard of Adrenic acid. This product is intended for research and analytical applications. Adrenic Acid (cis-7,10,13,16-Docosatetraenoic acid) is a naturally polyunsaturated fatty acid in the adrenal gland, brain, kidney, and vasculature. Adrenic Acid can regulate the vascular tone in arteries of the adrenal cortex. Adrenic Acid also is an inflammation enhancer in non-alcoholic fatty liver disease .

HY-12756A

E6446 dihydrochloride 1 Publications Verification	Toll-like Receptor (TLR) Stearoyl-CoA Desaturase (SCD)	Metabolic Disease Inflammation/Immunology
E6446 dihydrochloride is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 dihydrochloride is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 dihydrochloride also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD) .

HY-12756

E6446 1 Publications Verification	Toll-like Receptor (TLR) Stearoyl-CoA Desaturase (SCD)	Metabolic Disease Inflammation/Immunology
E6446 is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD) .

HY-130437

p-nitro-Pifithrin-α	MDM-2/p53 TGF-β Receptor Caspase	Infection Metabolic Disease
p-nitro-Pifithrin-α, a cell-permeable analog of pifithrin-α, is a potent p53 inhibitor. p-nitro-Pifithrin-α suppresses p53-mediated TGF-β1 expression in HK-2 cells. p-nitro-Pifithrin-α inhibits the activation of caspase-3 by Zika virus (ZIKV) strains. p-nitro-Pifithrin-α attenuates steatosis and liver injury in mice fed a high-fat diet [4]. non-alcoholic fatty liver disease .

HY-143862

Pparδ agonist 7	PPAR	Metabolic Disease
Pparδ agonist 7 is a potent agonist of Pparδ. The peroxisome proliferator-activated receptor (PPAR) is a member of the intranuclear receptor transcription factor superfamily that plays a key role in the regulation of metabolic homeostasis, inflammation, cell growth and differentiation in vivo. Pparδ agonist 7 has the potential for the research of non-alcoholic fatty liver disease (NAFLD) (extracted from patent WO2019105234A1, compound TM4) .

HY-143863

PPARδ agonist 8	PPAR	Metabolic Disease
Pparδ agonist 8 is a potent agonist of Pparδ. The peroxisome proliferator-activated receptor (PPAR) is a member of the intranuclear receptor transcription factor superfamily that plays a key role in the regulation of metabolic homeostasis, inflammation, cell growth and differentiation in vivo. Pparδ agonist 8 has the potential for the research of non-alcoholic fatty liver disease (NAFLD) (extracted from patent WO2021169769A1, compound TM2) .

HY-W439487

7,9-Dimethylguanine	Others	Metabolic Disease
7,9-Dimethylguanine is a modified nucleotide base whose content in urine and serum of patients with alcoholic liver disease (ALD) is closely related to the severity of ALD. The free nucleotides/bases in urine and serum samples of ALD patients and controls were extracted and quantified by untargeted and nontargeted metabolomics methods, and 39 free nucleotides/bases were found in urine and 40 in serum, of which 12 and 11 modified nucleotide bases were significantly changed in patient samples (q < 0.05 and fold-change > 20%). The content of 7,9-Dimethylguanine in urine and 2-methylthio-N6-serine carbamoyl adenosine (ms2t6A) in serum were strongly associated with the severity of ALD, with Spearman rank correlation coefficients of 0.66 and 0.74 with Model for End-stage Liver Disease (MELD) scores, respectively. Notably, the levels of these two metabolites varied sufficiently to distinguish severe alcoholic hepatitis (AH) from non-severe ALD, and non-severe ALD from healthy controls.

HY-159595

PCSK9-IN-29	LDLR PCSK9	Metabolic Disease Inflammation/Immunology
PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity .

HY-146398

AMPK activator 6	AMPK	Metabolic Disease
AMPK activator 6 (Compound GC) reduces lipid content and activates the AMPK pathway in HepG2 and 3T3-L1 cells. AMPK activator 6 significantly suppresses the increase in triglyceride (TG) , total cholesterol (TC), low-density lipoprotein-C (LDL-C), and other biochemical indices in blood serum. AMPK activator 6 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome .

HY-W018392S

Mono-(2-ethylhexyl) phthalate-d4 MEHP-d₄; Phthalic acid mono-2-ethylhexyl ester-d₄	Isotope-Labeled Compounds	Metabolic Disease
Mono-(2-ethylhexyl) phthalate-d₄ is a deuterium labeled Mono-(2-ethylhexyl) phthalate (HY-W018392). Mono-(2-ethylhexyl) phthalate (MEHP) is a major bioactive metabolite of diethylhexyl phthalate (DEHP). Mono-(2-ethylhexyl) phthalate can promote fatty acid synthesis in hepatocytes by regulating the expression of relevant genes and proteins, contributing to non-alcoholic fatty liver disease (NAFLD) .

HY-W018392R

Mono-(2-ethylhexyl) phthalate (Standard)	Endogenous Metabolite	Metabolic Disease
Mono-(2-ethylhexyl) phthalate (Standard) is the analytical standard of Mono-(2-ethylhexyl) phthalate. This product is intended for research and analytical applications. Mono-(2-ethylhexyl) phthalate (MEHP) is a major bioactive metabolite of diethylhexyl phthalate (DEHP). Mono-(2-ethylhexyl) phthalate can promote fatty acid synthesis in hepatocytes by regulating the expression of relevant genes and proteins, contributing to non-alcoholic fatty liver disease (NAFLD) .

HY-161926

YGT-31	PPAR	Metabolic Disease
YGT-31 is a modulator for PPARγ with an IC₅₀ of 1.72 μM, and a K_i of 0.62 μM. YGT-31 reduces blood glucose levels and improves insulin resistance in db/db mice type 2 diabetes models, through inhibition of CDK5-mediated PPARγ-Ser273 phosphorylation. YGT-31 exhibits anti-hepatic steatosis effect in mice non-alcoholic fatty liver disease (NAFLD) model .

HY-155156

PF-07238025	Endogenous Metabolite	Cardiovascular Disease
PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC₅₀=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice .

HY-155157

PF-07247685	Endogenous Metabolite	Cardiovascular Disease
PF-07247685 is a BCKDC kinase (BDK) inhibitor (EC₅₀=2.2 nM). PF-07247685 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07247685 improved cardiometabolic endpoints and improves glucose tolerance in mice .

HY-161211

HSD17B13-IN-7	17β-HSD iGluR	Metabolic Disease
HSD17B13-IN-7 (compound 1), a fluorophenol-containing compound, is a potent HSD17B13 inhibitor with IC₅₀s of 0.18 μM and 0.25 μM β-estradiol and Leukotriene B4 as substrates, respectively. HSD17B13-IN-7 is a potent N-methyl-D-aspartate (NMDA) NR2B receptor antagonist. HSD17B13-IN-7 has the potential for non-alcoholic fatty liver disease research .

HY-N6850

Calenduloside E 1 Publications Verification	Apoptosis Pyroptosis AMPK Bcl-2 Family JAK STAT Calcium Channel Interleukin Related TNF Receptor SOD Reactive Oxygen Species PPAR	Cardiovascular Disease Inflammation/Immunology
Calenduloside E is a pentacyclic triterpenoid saponin that can be extracted from the bark and roots of Aralia ovata, and has anti-inflammatory and anti-apoptotic activities. Calenduloside E alleviates atherosclerosis by regulating macrophage polarization, improves mitochondrial function by regulating the AMPK-SIRT3 pathway, and alleviates acute liver injury. In addition, Calenduloside E promotes the interaction between L-type calcium channels and Bcl-2 related apoptosis genes, inhibits calcium overload, and alleviates myocardial ischemia/reperfusion injury. Calenduloside E also improves non-alcoholic fatty liver disease by regulating heat shock-dependent pathways, and inhibits ROS mediated JAK1-STAT3 pathways to reduce cellular inflammatory responses .

HY-100443

PX20606 PX-102	FXR	Cancer
PX20606 is an orally active agonist for farnesoid X receptor (FXR), with EC₅₀ 220 nM (mFXR) and 50 nM (hFXR), measured by Gal4-FXR assay. PX20606 induces the expression of tumor suppressor gene NDRG2, inhibits the tumor growth and metastasis in mouse HCC model. PX20606 exhibits hepatoprotective efficacy .

Cat. No.	Product Name

HY-L199

*Non-Alcoholic* Fatty Liver Disease (NAFLD) Compound Library**	3,225 compounds
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary. MCE designs a unique collection of 3,225 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

3,225 compounds

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary.

MCE designs a unique collection of 3,225 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.

PRDX3(103-112) SO3 modified, human	Ferroptosis	Metabolic Disease
PRDX3(103-112) SO3 modified, human is a marker of ferroptosis, and can be used for liver diseases study .

Zeaxanthin dipalmitate Physalien	Classification of Application Fields Terpenoids Source classification Diterpenoids Plants Solanaceae Lycium chinense Miller Disease Research Fields Inflammation/Immunology	Adiponectin Receptor P2X Receptor Autophagy
Zeaxanthin dipalmitate (Physalien) is a wolfberry-derived carotenoid, has anti-inflammatory and anti-oxidative stress effects. Zeaxanthin dipalmitate directly interact with p2X7 receptor (K_d=81.2 nM) and adiponectin receptor 1 (AdipoR1; K_d=533 nM) in a positive dose-dependent manner. Zeaxanthin dipalmitate restores mitochondrial autophagy functions suppressed by ethanol intoxication. Zeaxanthin dipalmitate can be used in the research of alcoholic fatty liver disease (AFLD) and retinitis pigmentosa (RP) .

1-Palmitoyl-sn-glycerol 3-phosphate 1-P-GPA	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Others
1-Palmitoyl-sn-glycerol 3-phosphate (1-P-GPA) is an endogenous metabolite. 1-Palmitoyl-sn-glycerol 3-phosphate can be used for the research of non‐alcoholic fatty liver disease .

Cat. No.	Product Name	Chemical Structure

HY-W018392S

Mono-(2-ethylhexyl) phthalate-d4

Mono-(2-ethylhexyl) phthalate-d₄ is a deuterium labeled Mono-(2-ethylhexyl) phthalate (HY-W018392). Mono-(2-ethylhexyl) phthalate (MEHP) is a major bioactive metabolite of diethylhexyl phthalate (DEHP). Mono-(2-ethylhexyl) phthalate can promote fatty acid synthesis in hepatocytes by regulating the expression of relevant genes and proteins, contributing to non-alcoholic fatty liver disease (NAFLD) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks